Verastem, Inc. (VSTM)
VSTM moved a median of -0.09% 30 minutes after news, and -1.14% by the close. How VSTM actually reacts to news — the realized, point-in-time move the market made, measured across 411 labeled events over the last three years with zero look-ahead.
VSTM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 41% | 409 |
| 30-min | -0.09% | 48% | 411 |
| 60-min | -0.45% | 44% | 411 |
| to close | -1.14% | 38% | 407 |
| Middle 50% of VSTM reactions | -1.74% to +1.60% |
|---|---|
| Median reaction (30-min) | -0.09% |
| Measured reactions | 411 |
Half of all Verastem, Inc. news events land between -1.74% and +1.60% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How VSTM reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 20 | +0.43% | 65% | +2.20% |
| Analyst downgrades | 16 | +0.24% | 50% | +0.88% |
| Coverage initiations | 18 | +2.27% | 67% | -1.99% |
| Rating reiterations | 72 | -0.21% | 44% | -0.75% |
| Price-target cuts | 14 | -0.77% | 14% | -1.52% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how VSTM ranks against every other measured name →
That’s how VSTM usually reacts — get an email when it moves on news →Email me when VSTM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VSTM's baseline. Nothing else.
Recent VSTM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.92% | -4.08% | |
| Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026 | Press release | Business Wire | -0.82% | -3.15% | |
| Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer | Press release | Business Wire | -1.41% | +1.80% | |
| Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting | Press release | Business Wire | -0.49% | -3.70% | |
| Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers | Press release | Business Wire | -2.93% | -1.46% | |
| Verastem Oncology to Participate in Upcoming September Investor Conferences | Press release | Business Wire | +2.66% | +4.16% | |
| Form 8-K Verastem, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +3.38% | +1.35% | |
| Form 10-Q Verastem, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.38% | +1.35% | |
| Form 8-K Verastem, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +3.38% | +1.35% | |
| Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates | Press release | Business Wire | +3.38% | +1.35% | |
| Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer | Press release | Business Wire | +0.55% | -3.69% | |
| Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | Business Wire | +0.17% | +5.28% | |
| Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer | Press release | Business Wire | +0.17% | +5.28% | |
| Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.11% | -1.33% | |
| Form 8-K Verastem, Inc. For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +1.92% | -8.33% | |
| VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors | Press release | Business Wire | +1.92% | -8.33% | |
| Form 8-K Verastem, Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +2.20% | +1.96% | |
| Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer | Press release | Business Wire | +2.20% | +1.96% | |
| Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer | Press release | Business Wire | +2.20% | +1.96% | |
| Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program | Press release | Business Wire | +0.13% | +0.00% | |
| Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Press release | Business Wire | +0.13% | +2.66% | |
| Form S-8 Verastem, Inc. | SEC filing · Form S-8 | SEC EDGAR | -3.00% | -3.23% | |
| Verastem Oncology to Present at Jefferies Healthcare Conference | Press release | Business Wire | -0.69% | -2.97% | |
| Form 8-K Verastem, Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +1.14% | -0.23% | |
| Verastem Oncology Appoints Michael P. Bailey to its Board of Directors | Press release | Business Wire | +1.14% | -0.23% | |
| Verastem Oncology to Present at Upcoming Investor Conferences | Press release | Business Wire | +0.00% | -6.08% | |
| On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer | Press release | Business Wire | -3.21% | -10.28% | |
| Form 10-Q Verastem, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.21% | -10.28% | |
| Form 8-K Verastem, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -3.21% | -10.28% | |
| Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates | Press release | Business Wire | -3.21% | -10.28% | |
| Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer | Press release | Business Wire | -0.73% | -0.55% | |
| Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | Business Wire | +0.98% | +2.30% | |
| Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers | Press release | Business Wire | -0.90% | -4.84% | |
| Form DEF 14A Verastem, Inc. For: May 21 | SEC filing · Form DEF | SEC EDGAR | -0.90% | -4.84% | |
| Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.18% | -2.84% | |
| Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers | Press release | Business Wire | -0.53% | -1.94% | |
| Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 | Press release | Business Wire | -0.53% | -1.94% | |
| Form 10-K Verastem, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +6.89% | +3.36% | |
| Form 8-K Verastem, Inc. For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +6.89% | +3.36% | |
| Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates | Press release | Business Wire | +6.89% | +3.36% | |
| Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 | Press release | Business Wire | +0.33% | -2.73% | |
| Form 8-K Verastem, Inc. For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | +2.49% | +5.76% | |
| Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers | Press release | Business Wire | +2.49% | +5.76% | |
| Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -2.67% | +1.12% | |
| Form 8-K Verastem, Inc. For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +2.09% | -4.06% | |
| Form 8-K Verastem, Inc. For: Dec 29 | SEC filing · Form 8-K | SEC EDGAR | -0.13% | +2.39% | |
| Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer | Press release | Business Wire | +0.52% | -1.70% | |
| Form 8-K Verastem, Inc. For: Dec 15 | SEC filing · Form 8-K | SEC EDGAR | +1.94% | +2.33% | |
| Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth | Press release | Business Wire | +1.92% | -5.47% | |
| Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference | Press release | Business Wire | +2.80% | +2.50% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VSTM section they belong to.
Where else VSTM is measured.
VSTM earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Zai Lab Limited - American Depositary Shares (ZLAB) | 415 | 0.00% | 49% |
| Bausch Health Companies Inc. (BHC) | 412 | +0.06% | 50% |
| Alphatec Holdings, Inc. (ATEC) | 409 | -0.18% | 45% |
| Align Technology, Inc. (ALGN) | 407 | -0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Verastem, Inc.'s median reaction calculated?
Every labeled VSTM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 411 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of VSTM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VSTM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.